James Loerop - Feb 1, 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Business Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol: ACRS
Transactions as of: Feb 1, 2024
Transactions value $: -$7,705
Form type: 4
Date filed: 2/5/2024, 07:29 PM
Previous filing: Aug 28, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+11.3K	+51.87%		32.9K	Feb 1, 2024	Direct	F1
transaction	ACRS	Common Stock	Tax liability	-$4.62K	-3.85K	-11.7%	$1.20	29.1K	Feb 1, 2024	Direct	F2
transaction	ACRS	Common Stock	Options Exercise		+7.5K	+25.79%		36.6K	Feb 1, 2024	Direct	F1
transaction	ACRS	Common Stock	Tax liability	-$3.08K	-2.57K	-7.02%	$1.20	34K	Feb 1, 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-11.3K	-33.33%	$0.00	22.5K	Feb 1, 2024	Common Stock	11.3K		Direct	F1, F3
transaction	ACRS	Restricted Stock Unit	Options Exercise	$0	-7.5K	-25%	$0.00	22.5K	Feb 1, 2024	Common Stock	7.5K		Direct	F1, F4
transaction	ACRS	Employee Stock Option (Right to Buy)	Award	$0	+207K		$0.00	207K	Feb 1, 2024	Common Stock	207K	$1.20	Direct	F5
transaction	ACRS	Restricted Stock Units	Award	$0	+59K		$0.00	59K	Feb 1, 2024	Common Stock	59K		Direct	F1, F6
transaction	ACRS	Restricted Stock Units	Award	$0	+148K		$0.00	148K	Feb 1, 2024	Common Stock	148K		Direct	F1, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3	The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F4	The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F5	Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F6	The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F7	50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.